Location of Repository

Cyclooxygenase-2 expression and its association with thyroid lesions

By Kinga Krawczyk-Rusiecka and Andrzej Lewiński


Cyclooxygenase (COX), also known as prostaglandin H synthase, catalyses the formation of prostaglandins from arachidonic acid. It can be expressed in response to various stimuli, such as hormones, mitogens, cytokines, other inflammatory mediators and growth factors. The product of COX-2 activity has been implicated in carcinogenesis by promoting angiogenesis, inhibiting apoptosis, increasing cell invasion and stimulating cell proliferation. It has also been proved that the regular intake of non-steroidal anti-inflammatory drugs (NSAIDs) decreases the risk of developing colon and breast cancers. Thus, it speaks for an important role of COX-2 in growth processes of various types of neoplasms. The connection between COX-2 activity and carcinogenesis has also been examined in human thyroid neoplasms. COX-2 overexpression has been reported in thyroid cancers and also in inflammatory conditions. In consequence there is significant interest whether COX-2 could be of importance as a molecular marker of malignancy in the case of thyroid carcinoma

Topics: Review Paper
Publisher: Termedia Publishing House
OAI identifier: oai:pubmedcentral.nih.gov:3298330
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2006). 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal antiinflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat
    2. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell
    3. (2002). An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for
    4. (1995). Aspirin and the risk of colorectal cancer in women.
    5. (1991). Aspirin use and reduced risk of fatal colon cancer.
    6. (2008). Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability.
    7. (1998). Chemo -preventive activity of celecoxib, a specific cyclooxygenase2 inhibitor, against colon carcinogenesis. Cancer Res
    8. (2001). Chemoprevention of intestinal polyposis in the Apc∆716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res
    9. (2000). COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer
    10. (1999). Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest
    11. (2000). Cyclooxygenase-2 expression in Helicobacter pylori–associated premalignant and malignant gastric lesions.
    12. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
    13. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res
    14. (2002). Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope
    15. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res
    16. (2005). Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland. Virch Arch
    17. (2001). Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res
    18. (2002). Cyclooxygenase-2expression during carcinogenesis in the human stomach.
    19. (2001). Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol
    20. (2001). Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology
    21. (1996). Down-regulation of cytokineinduced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation.
    22. (1997). Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin.
    23. (2005). Evaluation of insulinlike growth factor II, cyclooxygenase-2, ets-1 and thyroidspecific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
    24. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.
    25. (1999). Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology
    26. (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res
    27. (2002). Fahey TJ III. Cyclooxygenase-2 expression in thyroid nodules.
    28. (1982). Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care.
    29. (1989). High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene
    30. (2005). High prevalence of cylooxygenase 2 expression in papillary thyroid carcinoma.
    31. (1992). Human cyclooxygenase-2 cDNA.
    32. (2005). Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid. Arch Pathol Lab Med
    33. (1998). Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s and associated adenocarcinomas. Cancer Res
    34. (2007). Increased incidence of well differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of PI3k/Akt Pathway.
    35. (2000). Inducible cyclooxygenase-2 gene expression in the human thyroid epithelial cell line Nthy-ori3-1. Inflamm Res
    36. (1998). Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway.
    37. (2008). Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer?
    38. (2003). Methanolic extract of adlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.
    39. (1993). Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response tocytokines.
    40. (2001). Molecular pathology of cyclooxygenase-2-cancer-induced angiogenesis. Ann Clin Lab Sci
    41. (2001). Overexpression of cyclo -oxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res
    42. (1999). Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res
    43. (2009). Pathophysiology of cyclooxygenase inhibition in animal models. Toxicol Pathol
    44. (1990). Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol
    45. (1996). Prostaglandin synthase 2. Biochim Biophys Acta
    46. (1955). Relation of thyroid neoplasm to Hashimoto disease of the thyroid gland. AMA Arch Surg
    47. (1998). Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication of the histological implications. Human Pathol
    48. (2005). Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol
    49. (2000). Signaling through Ras is essential for ret oncogene – induced cell differentiation in PC12 cells.
    50. (2008). Soh EY. Cyclooxygenase-2 expression in human thyroid disease.
    51. (1996). Suppression of intestinal polyposis
    52. (2000). TGF-1 enhances Ha-Rasinduced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.
    53. (2000). The role of cyclooxygenase-2 in ulcerative colitis–associated neoplasia.
    54. (1994). Up-regulation of cyclo -oxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology
    55. (2002). Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors.
    56. (1997). Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
    57. (2006). VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.